A phase 2a, double-masked, randomized, vehicle-controlled trial of VVN001 in subjects with dry eye disease

Evaluate the initial ocular safety and tolerability and efficacy of VVN001 Ophthalmic Solution (VVN001), a small-molecule antagonist of lymphocyte function-associated antigen-1 (LFA-1), in subjects with dry eye disease (DED). This was a multi-center, double-masked, randomized, dose-response, vehicle...

Full description

Saved in:

Bibliographic Details
Published in:	The ocular surface 2023-04, Vol.28, p.18-24
Main Authors:	Tauber, Joseph, Evans, David, Segal, Bruce, Li, Xiao-Yan, Shen, Wang, Lu, Caroline, Novack, Gary D., Abrams, Marc, Smyth-Medina, Robert, Majmudar, Parag, Holland, Edward, Alpern, Louis, Martel, Joseph, Clay, Emma, Korenfeld, Michael, Goosey, John, Goldberg, Damien, El-Harazi, Sherif
Format:	Article
Language:	eng
Subjects:	Cornea Dry eye disease Symptoms VVN001
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Evaluate the initial ocular safety and tolerability and efficacy of VVN001 Ophthalmic Solution (VVN001), a small-molecule antagonist of lymphocyte function-associated antigen-1 (LFA-1), in subjects with dry eye disease (DED). This was a multi-center, double-masked, randomized, dose-response, vehicle-controlled, parallel-group study conducted in 170 subjects with DED. Subjects were randomized to receive VVN001 (1% or 5%) or its vehicle, twice-daily in both eyes for 84 days. The primary outcome measure was inferior region corneal fluorescein staining (iCFS, 0–4 scale) at Day 84. Visual Analogue Scale eye dryness (VAS, 0–100 scale) was a secondary outcome. The primary and first secondary outcomes were not met. At Day 84 treatment effects in favor of VVN001 5% relative to its vehicle for iCFS were 0.29 units (p = 0.054), and for VAS were 3.18 units (p = 0.533). In other secondary outcomes, treatment effects in favor of VVN001 5% relative to its vehicle were seen in total CFS (1.61 units, 0–20 scale, p = 0.004) and Schirmer score (1.77 and 2.32 mm, p = 0.049 and p = 0.17 at Days 14 and 28 respectively). Adverse events of incidence 5% or greater in either active treatment group were instillation site pain (3/57, 5.3%), dysgeusia (3/56, 5.4%) and urinary tract infection (3/57, 5.3%). There were no major safety issues of note. Appropriately powered studies will be required with a priori selection of the efficacy endpoints to evaluate VVN001's therapeutic potential.
ISSN:	1542-0124 1937-5913